Please login to the form below

Not currently logged in
Email:
Password:

corticosteroid fluticasone furoate

This page shows the latest corticosteroid fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

GSK preps COPD filing for asthma pioneer Nucala

GSK preps COPD filing for asthma pioneer Nucala

Aside from Nucala, GSK is pinning its near-term hopes on dolutegravir-based HIV therapies and its closed triple therapy for COPD – delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta

Latest news

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... protect its

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... These include

  • GSK brings forward triple COPD therapy filing in US GSK brings forward triple COPD therapy filing in US

    The once-daily therapy developed by GSK and Innoviva (formerly Theravance) comprises corticosteroid fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three

  • FDA panel backs GSK's asthma drug Breo for adults only FDA panel backs GSK's asthma drug Breo for adults only

    The product is sold as Relvar in some markets and is a follow-up to GSK's blockbuster Seretide/Advair product and combines LABA vilanterol with the inhaled corticosteroid (ICS) fluticasone ... furoate. The FDA's panel of experts said the safety and

  • GSK trial throws everything at COPD GSK trial throws everything at COPD

    Tests combination of fluticasone furoate, umeclidinium and vilanterol. GlaxoSmithKline and partner Theravance have started a phase III trial of a triple therapy for chronic obstructive pulmonary disease (COPD) delivered using a ... The two companies will

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics